Why was the GAAP loss so large in 2025?

The GAAP loss was driven primarily by a non-cash goodwill impairment of $6.7 billion recorded in Q3 2025 after market conditions in July 2025, including the One Big Beautiful Bill Act and a decline in the stock price, prompted a quantitative impairment test. A further $513 million Magellan Health impairment was recorded in Q4 2025. These charges are non-cash and are excluded from adjusted EPS.

What is driving the margin pressure, and is it improving?

Medical cost ratios rose sharply, with full-year HBR at 91.9% versus 88.3% in 2025. Key drivers were higher Marketplace morbidity, lower Marketplace risk adjustment revenue, PDP program changes under the Inflation Reduction Act, and higher Medicaid costs in behavioral health, home health, and high-cost drugs. Management reports Medicaid improving sequentially and says Q4 Marketplace and Medicare Advantage trends were consistent with expectations, though the Q4 Commercial HBR included about 100 bps of unfavorable net out-of-period items.

What does 2026 guidance imply for earnings and margins?

Guidance calls for adjusted diluted EPS above $3.00, a substantial rebound from $2.08 in 2025, with HBR of 90.9%-91.7% versus 91.9% in 2025. Management expects a Medicaid HBR improvement of about 95 bps, partly offset by PDP HBR increases. Guidance also assumes SG&A of 7.1%-7.7%, a 27%-28% effective tax rate, interest expense of $620-650 million, and a Medicaid net rate increase in the mid-4% range.

Is Centene's balance sheet under strain?

Leverage has increased. Debt-to-capitalization rose to 46.5% at year-end 2025 from 41.2% a year earlier, as shareholders' equity fell to $20.0 billion after the goodwill impairment. Total debt is $17.4 billion, and the company reported no borrowings on its $4.0 billion revolver. Cash available for general corporate use was only $400 million, though total cash, investments and restricted deposits were $38.8 billion, largely held in regulated subsidiaries. Management has emphasized continued debt reduction in 2026.

What is the impact of the Magellan Health divestiture?

Centene signed a definitive agreement in December 2025 to divest the remaining Magellan Health businesses and recorded $513 million in pre-tax impairment charges ($389 million after-tax) tied to the pending sale. The filing does not disclose the sale price or expected closing timeline in this release, so investors should watch subsequent disclosures for the transaction terms and any further impact on earnings or cash flow.

CNC 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 6, 2026. Cited figures are marked; the original filing is the authoritative source.

Centene reported a challenging fourth quarter and full year 2025, with GAAP results heavily distorted by non-cash charges.

Full-year GAAP diluted loss per share was $(13.53), driven mainly by a $6.7 billion^a goodwill impairment recorded in Q3 2025, plus a $513 million Magellan Health impairment tied to the pending divestiture of its remaining Magellan businesses. Excluding these items, full-year adjusted diluted EPS was $2.08, versus $7.17 in 2024, while Q4 adjusted diluted loss per share was $(1.19). The core driver of the earnings decline was medical cost pressure: the consolidated health benefits ratio rose to 91.9% for the year (from 88.3%) and to 94.3% in Q4, with Commercial/Marketplace morbidity the primary culprit, along with PDP program changes under the Inflation Reduction Act and higher Medicaid behavioral health and home health costs.

Management says Marketplace and Medicaid trends are stabilizing, with Medicaid HBR improving 40 basis points sequentially in Q4 to 93.0%. Looking ahead, Centene guided to 2026 adjusted diluted EPS greater than $3.00^b and GAAP diluted EPS greater than $1.98, with an HBR of 90.9%-91.7% and premium and service revenue of $170-174 billion. Guidance implies a meaningful margin recovery, with the consolidated HBR expected to improve roughly 35-40 basis points at the midpoint, driven by a roughly 95 basis point Medicaid-related improvement offset partly by PDP and other mix effects.

Balance sheet items warrant attention: total debt was $17.4 billion^c, debt-to-capitalization rose to 46.5%, cash available for general corporate use was only $400 million, and days in claims payable fell to 46. Management emphasized continued debt reduction and a Medicaid net rate increase in the mid-4% range for 2026.

For investors, the key questions are whether the 2026 margin recovery materializes, particularly in Marketplace where morbidity pressure has been most severe, and whether Medicaid cost trends continue to stabilize. The guidance represents a clear inflection narrative, but it depends heavily on execution in government and exchange businesses that have proven volatile, and the 2025 goodwill write-down signals that the earnings base has been reset materially lower.

02—Key points

Key Highlights

FY2025 GAAP diluted loss per share of $(13.53), driven by a $6.7 billion goodwill impairment; adjusted diluted EPS was $2.08 versus $7.17 in 2024.
Q4 2025 consolidated HBR of 94.3% (vs. 89.6% a year ago), with Commercial HBR of 95.4% running about 100 bps above expectations due to net out-of-period items; Medicaid HBR improved 40 bps sequentially to 93.0%.
2026 guidance calls for adjusted diluted EPS greater than $3.00 and GAAP diluted EPS greater than $1.98, with total revenues of $186.5-190.5 billion.
2026 HBR guidance of 90.9%-91.7% implies roughly 35-40 bps of consolidated improvement at the midpoint, with Medicaid expected to contribute about 95 bps of improvement.
Membership reached 27.6 million at year-end 2025, up from 25.9 million at year-end 2024 (excluding TRICARE), driven by Marketplace (5.5 million) and PDP (8.1 million) growth, while Traditional Medicaid declined.
Balance sheet pressure: total debt of $17.4 billion, debt-to-capitalization of 46.5% (up from 41.2%), and only $400 million of cash available for general corporate use.
Pending divestiture of the remaining Magellan Health businesses triggered $513 million in pre-tax impairment charges ($389 million after-tax).

03—Questions

Frequently Asked Questions

Why was the GAAP loss so large in 2025?
The GAAP loss was driven primarily by a non-cash goodwill impairment of $6.7 billion recorded in Q3 2025 after market conditions in July 2025, including the One Big Beautiful Bill Act and a decline in the stock price, prompted a quantitative impairment test. A further $513 million Magellan Health impairment was recorded in Q4 2025. These charges are non-cash and are excluded from adjusted EPS.
What is driving the margin pressure, and is it improving?
Medical cost ratios rose sharply, with full-year HBR at 91.9% versus 88.3% in 2025. Key drivers were higher Marketplace morbidity, lower Marketplace risk adjustment revenue, PDP program changes under the Inflation Reduction Act, and higher Medicaid costs in behavioral health, home health, and high-cost drugs. Management reports Medicaid improving sequentially and says Q4 Marketplace and Medicare Advantage trends were consistent with expectations, though the Q4 Commercial HBR included about 100 bps of unfavorable net out-of-period items.
What does 2026 guidance imply for earnings and margins?
Guidance calls for adjusted diluted EPS above $3.00, a substantial rebound from $2.08 in 2025, with HBR of 90.9%-91.7% versus 91.9% in 2025. Management expects a Medicaid HBR improvement of about 95 bps, partly offset by PDP HBR increases. Guidance also assumes SG&A of 7.1%-7.7%, a 27%-28% effective tax rate, interest expense of $620-650 million, and a Medicaid net rate increase in the mid-4% range.
Is Centene's balance sheet under strain?
Leverage has increased. Debt-to-capitalization rose to 46.5% at year-end 2025 from 41.2% a year earlier, as shareholders' equity fell to $20.0 billion after the goodwill impairment. Total debt is $17.4 billion, and the company reported no borrowings on its $4.0 billion revolver. Cash available for general corporate use was only $400 million, though total cash, investments and restricted deposits were $38.8 billion, largely held in regulated subsidiaries. Management has emphasized continued debt reduction in 2026.
What is the impact of the Magellan Health divestiture?
Centene signed a definitive agreement in December 2025 to divest the remaining Magellan Health businesses and recorded $513 million in pre-tax impairment charges ($389 million after-tax) tied to the pending sale. The filing does not disclose the sale price or expected closing timeline in this release, so investors should watch subsequent disclosures for the transaction terms and any further impact on earnings or cash flow.

04—Continue

← View all 8-K filings